上海萊士(002252.SZ):擬42億元收購南嶽生物100%股權
格隆匯3月26日丨上海萊士(002252.SZ)公佈,爲推進上海萊士血液製品股份有限公司“拓漿”和“脫漿”齊步走戰略,進一步拓展公司血漿資源和優質生產基地,公司於2025年3月26日在湖南省衡陽市與劉令安、長沙德信生物技術合夥企業(有限合夥)、陳玉、肖漢族、王香英(以下合稱“87.9766%股權轉讓方”)及南嶽生物製藥有限公司(以下簡稱“南嶽生物”或“標的公司”)簽署《關於南嶽生物製藥有限公司之股權轉讓協議》(以下簡稱《87.9766%股權轉讓協議》),收購該等轉讓方合計持有的南嶽生物87.9766%股權;與湖南興湘南嶽私募基金合夥企業(有限合夥)、湖南興湘隆銀高新產業投資合夥企業(有限合夥)(以下合稱“湖南興湘基金”或“12.0234%股權轉讓方”)及南嶽生物簽署《關於南嶽生物製藥有限公司12.0234%股權之股權轉讓協議》(以下簡稱《12.0234%股權轉讓協議》),收購湖南興湘基金合計持有的南嶽生物12.0234%股權(前述87.9766%股權轉讓、12.0234%股權轉讓合稱“本次交易”)。
本次交易基礎對價對應標的公司100%股權作價42億元,其中:87.9766%股權轉讓方以合計人民幣36.95億元的股權轉讓對價將其持有的南嶽生物87.9766%股權轉讓給上海萊士,湖南興湘基金以合計人民幣5.05億元的股權轉讓對價將其持有的南嶽生物12.0234%股權轉讓給上海萊士。
本次交易完成後,公司將直接持有南嶽生物100%股權,南嶽生物將成爲公司的全資子公司,南嶽生物合併報表範圍內全部實體(按照《87.9766%股權轉讓協議》約定從目標集團剝離的實體除外)納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.